Vaxcyte (PCVX) News Today $86.53 +0.32 (+0.37%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Goldman Sachs Initiates Coverage of Vaxcyte (PCVX) with Buy RecommendationDecember 21 at 4:50 AM | msn.comVaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia assetDecember 20 at 1:43 PM | msn.comVaxcyte initiated with a Buy at Goldman SachsDecember 20 at 1:43 PM | markets.businessinsider.comThe Goldman Sachs Group Begins Coverage on Vaxcyte (NASDAQ:PCVX)The Goldman Sachs Group began coverage on shares of Vaxcyte in a report on Friday. They set a "buy" rating and a $135.00 target price on the stock.December 20 at 8:31 AM | marketbeat.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of StockDecember 20 at 8:30 AM | insidertrades.comAndrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total value of $710,240.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company's stock, valued at $9,720,610.98. The trade was a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.December 19 at 4:35 PM | marketbeat.comKuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmDecember 19 at 12:16 PM | globenewswire.comLord Abbett & CO. LLC Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)Lord Abbett & CO. LLC lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 26.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 312,425 shares of the company's stock after purchasing an additional 66,183 shares durDecember 15, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Franklin Resources Inc.Franklin Resources Inc. lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 13.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,786,335 shares of the company's stock after buying anDecember 15, 2024 | marketbeat.comGeode Capital Management LLC Has $308.68 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)Geode Capital Management LLC raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 10.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,700,782 shares of the company's stock after buying an additional 259December 15, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Receives $147.50 Consensus Price Target from AnalystsDecember 15, 2024 | americanbankingnews.comVaxcyte, Inc. (NASDAQ:PCVX) Receives Average Recommendation of "Buy" from AnalystsVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokeragesDecember 12, 2024 | marketbeat.comWhy Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy”December 12, 2024 | msn.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells 2,366 Shares of StockDecember 11, 2024 | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) is Frazier Life Sciences Management L.P.'s 7th Largest PositionFrazier Life Sciences Management L.P. lowered its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 15.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 879,405 shares of the company's stock after selling 160,00December 10, 2024 | marketbeat.comY Intercept Hong Kong Ltd Has $2.97 Million Stake in Vaxcyte, Inc. (NASDAQ:PCVX)Y Intercept Hong Kong Ltd lifted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 148.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,019 shares of the companyDecember 10, 2024 | marketbeat.comZacks Investment Management Invests $1.56 Million in Vaxcyte, Inc. (NASDAQ:PCVX)Zacks Investment Management bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,645 shares of the company's stock, valued atDecember 10, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by State Street CorpState Street Corp raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 1.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,405,743 shares of the company's stock after acquiring an additional 38,596 shares during the quarterDecember 10, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) SVP Sells $457,450.00 in StockDecember 10, 2024 | insidertrades.comWhat Makes Vaxcyte (PCVX) An Investment Bet?December 9, 2024 | msn.comPier Capital LLC Sells 67,402 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Pier Capital LLC lowered its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 58.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,567 shares of the company's stock after seDecember 8, 2024 | marketbeat.comVaxcyte: Promising Developments and Strategic Advancements Boost Confidence in Stock PotentialDecember 6, 2024 | markets.businessinsider.comVaxcyte, Inc. (NASDAQ:PCVX) is RA Capital Management L.P.'s 2nd Largest PositionRA Capital Management L.P. grew its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 5.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,689,190 shares of the company's stock after purchasinDecember 5, 2024 | marketbeat.comPoint72 Asset Management L.P. Takes Position in Vaxcyte, Inc. (NASDAQ:PCVX)Point72 Asset Management L.P. acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 359,796 shares of the company'sDecember 5, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. lessened its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 45.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 54,000 shares of the company's stock after selDecember 5, 2024 | marketbeat.com27,433 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Bank of Montreal CanBank of Montreal Can purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 27,433 shares of the company's stock, valued at approximately $3,104,000. Other large investors have alDecember 5, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Position Trimmed by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC lowered its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 13.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 130,249 shares of the company's stock after selling 19,942 shares duDecember 4, 2024 | marketbeat.comMaven Securities LTD Acquires New Position in Vaxcyte, Inc. (NASDAQ:PCVX)Maven Securities LTD purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 129,700 shares of the company's stock, valued at approximately $14,821,0December 4, 2024 | marketbeat.comVaxcyte initiates Phase 2 study of VAX-31December 4, 2024 | markets.businessinsider.comJim Wassil Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockDecember 4, 2024 | insidertrades.com31,000 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by Bamco Inc. NYBamco Inc. NY bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 31,000 shares of the company's stock, valued at approximately $3,542,000. Several other institutioDecember 4, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stake in Vaxcyte, Inc. (NASDAQ:PCVX)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 38.0% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 408,274 shares of the company's stock aDecember 4, 2024 | marketbeat.comVaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in InfantsDecember 3, 2024 | globenewswire.comVaxcyte, Inc. (NASDAQ:PCVX) is HighVista Strategies LLC's 3rd Largest PositionHighVista Strategies LLC grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 38.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,661 shares of the company's stock after buying an additionalDecember 3, 2024 | marketbeat.com32,494 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Cinctive Capital Management LPCinctive Capital Management LP purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 32,494 shares of the company's stock, valued at approximately $3,713,000. SeveraDecember 3, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Has $17.94 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)The Manufacturers Life Insurance Company grew its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 19.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 157,024 sharesDecember 2, 2024 | marketbeat.comFred Alger Management LLC Reduces Stake in Vaxcyte, Inc. (NASDAQ:PCVX)Fred Alger Management LLC trimmed its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 5.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,243,717 shares of the company's stock after selling 66,719 shares during the pNovember 29, 2024 | marketbeat.comBraidwell LP Has $34 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)Braidwell LP decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 63.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 297,568 shares of the company's stock afteNovember 29, 2024 | marketbeat.comEventide Asset Management LLC Reduces Position in Vaxcyte, Inc. (NASDAQ:PCVX)Eventide Asset Management LLC cut its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 48.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 383,454 shares of the company's stock after selling 3November 29, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) is Acuta Capital Partners LLC's Largest PositionAcuta Capital Partners LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 22.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 135,400 shares of the company's stock after bNovember 28, 2024 | marketbeat.comVaxcyte (PCVX) Surged On Positive Phase 2 Data For Its DrugNovember 27, 2024 | msn.comFmr LLC Has $1.81 Billion Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)Fmr LLC lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 2.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,800,667 shares of the company's stock after selling 366November 27, 2024 | marketbeat.comCitigroup Inc. Buys 54,748 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Citigroup Inc. increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 33.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 220,543 shares of the company's stock afterNovember 27, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)Charles Schwab Investment Management Inc. lifted its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 47.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,295,837 shares of the company's stock afterNovember 25, 2024 | marketbeat.comNatixis Advisors LLC Grows Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)Natixis Advisors LLC increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 61.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,697 shares of the company's stock after purchasing an additional 8,606 shares duNovember 25, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Westfield Capital Management Co. LPWestfield Capital Management Co. LP trimmed its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 9.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,739,874 shares of the company's stockNovember 24, 2024 | marketbeat.comIntech Investment Management LLC Acquires Shares of 28,228 Vaxcyte, Inc. (NASDAQ:PCVX)Intech Investment Management LLC acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 28,228 shares of the company's stock, valued at approximately $3,226,00November 24, 2024 | marketbeat.comEagle Asset Management Inc. Trims Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)Eagle Asset Management Inc. reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 37.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 176,249 shares of the company's stock after selling 106,102 sharNovember 23, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Buys 26,096 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 59.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,037 sharNovember 23, 2024 | marketbeat.comB. Metzler seel. Sohn & Co. Holding AG Invests $1.19 Million in Vaxcyte, Inc. (NASDAQ:PCVX)B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,409 shares of the company's stock, vNovember 23, 2024 | marketbeat.com Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. PCVX Media Mentions By Week PCVX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCVX News Sentiment▼0.650.61▲Average Medical News Sentiment PCVX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCVX Articles This Week▼136▲PCVX Articles Average Week Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Moderna News Today Viatris News Today Summit Therapeutics News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Sarepta Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCVX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
